Zobrazeno 1 - 10
of 233
pro vyhledávání: '"Soedarsono Soedarsono"'
Publikováno v:
Jurnal Respirasi, Vol 10, Iss 3, Pp 203-208 (2024)
Introduction: The World Health Organization (WHO) has recommended the 9-month all-oral regimen for multidrug-resistant tuberculosis (MDR-TB) treatment. This regimen is expected to increase the treatment success rate. Bedaquiline, levofloxacin, and cl
Externí odkaz:
https://doaj.org/article/63b679bd6f974476a5ccc93d4661d138
Autor:
Soedarsono Soedarsono, MD, PhD, Sri Sarwosih Indah Marthaty, MD, Caesar Rozaq Auditiawan, MD, Anita Widyoningroem, MD
Publikováno v:
Radiology Case Reports, Vol 19, Iss 8, Pp 3162-3169 (2024)
The complication of hydropneumothorax and colovesical fistula is rare, especially in patients with tuberculosis (TB) and COVID-19. This particular situation poses a management difficulty, and can significantly threaten the patient's life without a cl
Externí odkaz:
https://doaj.org/article/b14e1a6490b542eaa991f558142644cc
Autor:
Deby Kusumaningrum, Ni Made Mertaniasih, Soedarsono Soedarsono, Rosy Setiawati, Canti Permata Pradipta
Publikováno v:
International Journal of Mycobacteriology, Vol 13, Iss 2, Pp 152-157 (2024)
Objective: GeneXpert Mycobacterium tuberculosis/rifampicin (MTB/RIF) is a conceptually helpful tool for establishing tuberculosis (TB) disease. Negative results from the GeneXpert test do not exclude the possibility of diagnosing non-tuberculous myco
Externí odkaz:
https://doaj.org/article/b639d407dbbf4077bc110275c6132a6c
Autor:
Soedarsono Soedarsono, Ni Made Mertaniasih, Tutik Kusmiati, Ariani Permatasari, Susi Subay, Suko Hari Adiono
Publikováno v:
International Journal of Mycobacteriology, Vol 13, Iss 2, Pp 140-146 (2024)
Background: Bedaquiline is one of the core drugs used to treat multidrug-resistant TB (MDR-TB). Delamanid is one of the companion drugs in group C which is used to complete the treatment regimen when drugs in groups A and B can not be used. This stud
Externí odkaz:
https://doaj.org/article/e3ebac929b1342199b6e6390cca0eaa3
Publikováno v:
Perspectives in Clinical Research, Vol 15, Iss 2, Pp 89-93 (2024)
Background: Bedaquiline and delamanid have been included in the individualized treatment regimen (ITR) to treat patients with drug-resistant tuberculosis (DR-TB). Objective: The objective of this study is to compare the effectiveness of sputum cultur
Externí odkaz:
https://doaj.org/article/57c8d30027d64e088344e7b7f14821cd
Autor:
Anindya Zalfaa Kusuma Dewi, Ronald Pratama A., Dody Taruna, Irmawati M. Dikman, Soedarsono Soedarsono, Yelvi Levani
Publikováno v:
Qanun Medika: Jurnal Kedokteran Fakultas Kedokteran Universitas Muhammadiyah Surabaya, Vol 8, Iss 02 (2024)
Tuberculosis (TB) is the most common opportunistic infection in people living with HIV/AIDS in Indonesia, and HIV infection promotes Mycobacterium tuberculosis infection. In ODHIV, the probability of contracting TB is 10% per year. According to the I
Externí odkaz:
https://doaj.org/article/7b8f4543f49f468fa4d03914a0b06066
Publikováno v:
In Indian Journal of Tuberculosis June 2024
Autor:
Setyawan, Muhamad Frendy, Mertaniasih, Ni Made, Soedarsono, Soedarsono, Artama, Wayan Tunas, Sohkichi Matsumoto
Publikováno v:
Journal of Medicinal & Chemical Sciences; Sep2024, Vol. 7 Issue 9, p1152-1162, 11p
Publikováno v:
Acta Medica Indonesiana, Vol 55, Iss 4 (2023)
Background: The use of bedaquiline has been reported to minimize the number of lost to follow-up and fewer rejections from the patients. This study is the first to depict the use of bedaquiline. It aims to provide information related to the profile o
Externí odkaz:
https://doaj.org/article/1157ee51f9ae4f63b6a452b373608d67
Publikováno v:
International Journal of Mycobacteriology, Vol 12, Iss 3, Pp 241-247 (2023)
Background: Bedaquiline is a core drug with an optimized background regimen for treating drug-resistant tuberculosis (DR-TB) patients. One of the adverse effects of bedaquiline is QT-corrected (QTc) interval prolongation. TB patients with diabetes me
Externí odkaz:
https://doaj.org/article/e7340dc588d846c4880d24ef4f8685bd